Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold

Journal of Medicinal Chemistry

Volumn 47, Issue 26, 2004, Pages 6595-6602

  Saitton, Stina ^a,b   Del Tredici, Andria L ^c   Mohell, Nina ^c,d   Vollinga, Roeland C ^e   Boström, Dan ^b   Kihlberg, Jan ^b,f   Luthman, Kristina ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c ACADIA PHARMACEUTICALS INC   (United States)

^d Preclinical R and D   (Sweden)

^e DSM RESOLVE   (Netherlands)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; N PROPYLAPOMORPHINE; PROLYLLEUCYLGLYCINAMIDE; PYRIDINE DERIVATIVE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; DRUG ACTIVITY; DRUG POTENTIATION; GRIGNARD REACTION; MOLECULAR MIMICRY; MOLECULAR MODEL; PEPTIDE SYNTHESIS; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ACETAMIDES; ANIMALS; APOMORPHINE; CRYSTALLOGRAPHY, X-RAY; DOPAMINE AGENTS; DRUG SYNERGISM; HUMANS; HYDROGEN BONDING; MICE; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; MSH RELEASE-INHIBITING HORMONE; NIH 3T3 CELLS; PROTEIN STRUCTURE, SECONDARY; PYRIDINES; RECEPTORS, DOPAMINE D2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10644269874     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049484q     Document Type: Article

References (51)

1. Hokfelt, T.; Broberger, C.; Xu, Z. Q. D.; Sergeyev, V.; Ubink, R.; Diez, M. Neuropeptides - An overview. Neuropharmacology 2000, 39, 1337-1356.
2. Giannis, A.; Rubsam, F. Peptidomimetics in Drug Design. Advances in Drug Research; Academic Press: London, 1997; pp 1-78.
3. Ripka, A. S.; Rich, D. H. Peptidomimetic design. Curr. Opin. Chem. Biol. 1998, 2, 441-452.
4. Hanessian, S.; McNaughtonSmith, G.; Lombart, H. G.; Lubell, W. D. Design and synthesis of conformationally constrained amino acids as versatile scaffolds and peptide mimetics. Tetrahedron 1997, 53, 12789-12854.
5. Souers, A. J.; Ellman, J. A. Beta-Turn mimetic library synthesis: Scaffolds and applications. Tetrahedron 2001, 57, 7431-7448.
6. Eguchi, M.; Shen, R. Y. W.; Shea, J. P.; Lee, M. S.; Kahn, M. Design, synthesis, and evaluation of opioid analogues with nonpeptidic beta-turn scaffold: Enkephalin and endomorphin mimetics. J. Med. Chem. 2002, 45, 1395-1398.
7. Le, G. T.; Abbenante, G.; Becker, B.; Grathwohl, M.; Halliday, J.; Tometzki, G.; Zuegg, J.; Meutermans, W. Molecular diversity through sugar scaffolds. Drug Discovery Today 2003, 8, 701-709.
8. Mishra, R. K.; Chiu, P.; Mishra, C. P. Pharmacology of L-Prolyl-L-Leucyl-Glycinamide (PLG): A Review. Methodol. Find. Exp. Clin. 1983, 5, 203-233.
9. Srivastava, L. K.; Bajwa, S. B.; Johnson, R. L.; Mishra, R. K. Interaction of L-Prolyl-L-Leucyl Glycinamide with Dopamine-D2 Receptor - Evidence for Modulation of Agonist Affinity States in Bovine Striatal Membranes. J. Neurochem. 1988, 50, 960-968.
10. Rajakumar, G.; Naas, F.; Johnson, R. L.; Chiu, S.; Yu, K. L.; Mishra, R. K. Down-Regulation of Halperidol-Induced Striatal Dopamine Receptor Supersensitivity by Active Analogues of L-Prolyl-L-Leucyl-Glycinamide (Plg). Peptides 1987, 8, 855-861.
11. Johnson, R. L.; Rajakumar, G.; Yu, K. L.; Mishra, R. K. Synthesis of Pro-Leu-Gly-NH2 Analogues Modified at the Prolyl Residue and Evaluation of Their Effects on the Receptor-Binding Activity of the Central Dopamine Receptor Agonist, ADTN. J. Med. Chem. 1986, 29, 2104-2107.
12. 2 Analogues Possessing Cyclic Amino-Acid-Residues at the C-Terminal Position. J. Med. Chem. 1986, 29, 2100-2104.
13. 2 Modified at the Leucyl Residue. J. Med. Chem. 1990, 33, 1828-1832.
14. Baures, P. W.; Pradhan, A.; Qjala, W. H.; Gleason, W. B.; Mishra, R. K.; Johnson, R. L. Synthesis and dopamine receptor modulating activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucyl- glycinamide (PLG). Bioorg. Med. Chem. Lett. 1999, 9, 2349-2352.
15. Evans, M. C.; Pradhan, A.; Venkatraman, S.; Qjala, W. H.; Gleason, W. B.; Mishra, R. K.; Johnson, R. L. Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring alpha,alpha-disubstituted amino acids. J. Med. Chem. 1999, 42, 1441-1447.
16. Thomas, C.; Ohnmacht, U.; Niger, M.; Gmeiner, P. beta-analogues of PLG (L-prolyl-L-leucyl-glycinamide): Ex-chiral pool syntheses and dopamine D-2 receptor modulating effects. Bioorg. Med. Chem. Lett. 1998, 8, 2885-2890.
17. Palomo, C.; Aizpurua, J. M.; Benito, A.; Miranda, J. I.; Fratila, R. M.; Matute, C.; Domercq, M.; Gago, F.; Martin-Santamaria, S.; Linden, A. Development of a new family of conformationally restricted peptides as potent nucleators of beta-turns. Design, synthesis, structure, and biological evaluation of beta-lactam peptide analogue of melanostatin. J. Am. Chem. Soc. 2003, 125, 16243-16260.
18. 2. J. Med. Chem. 1988, 31, 1430-1436.
19. Baures, P. W.; Ojala, W. H.; Costain, W. J.; Ott, M. C.; Pradhan, A.; Gleason, W. B.; Mishra, R. K.; Johnson, R. L. Design, synthesis, and dopamine receptor modulating activity of dike-topiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. J. Med. Chem. 1997, 40, 3594-3600.
20. 2. J. Med. Chem. 1993, 36, 3481-3483.
21. 2. J. Med. Chem. 1993, 36, 2356-2361.
22. 2. J. Med. Chem. 1993, 36, 256-263.
23. Khalil, E. M.; Ojala, W. H.; Pradhan, A.; Nair, V. D.; Gleason, W. B.; Mishra, R. K.; Johnson, R. L. Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl- glycinamide. J. Med. Chem. 1999, 42, 628-637.
24. Khalil, E. M.; Pradhan, A.; Ojala, W. H.; Gleason, W. B.; Mishra, R. K.; Johnson, R. L. Synthesis and dopamine receptor modulating activity of substituted bicyclic thiazolidine lactam peptidomimetics of L-prolyl-L-leucyl- glycinamide. J. Med. Chem. 1999, 42, 2977-2987.
25. Weber, K.; Ohnmacht, U.; Gmeiner, P. Enantiopure 4-and 5-aminopiperidin-2-ones: Regiocontrolled synthesis and conformational characterization as bioactive beta-turn mimetics. J. Org. Chem. 2000, 65, 7406-7416.
26. Dolbeare, K; Pontoriero, G. F.; Gupta, S. K.; Mishra, R. K.; Johnson, R. L. iso-lactam and reduced amide analogues of the peptidomimetic dopamine receptor modulator 3(R)-(2(S)pyrrolidinylcarbonyl)amino-2-oxo-1- pyrrolidineacetamide. Bioorg. Med. Chem. 2003, 11, 4103-4112.
27. Dolbeare, K.; Pontoriero, G. F.; Gupta, S. K.; Mishra, R. K.; Johnson, R. L. Synthesis and dopamine receptor modulating activity of 3-substituted gamma-lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide. J. Med. Chem. 2003, 46, 727-733.
28. Borg, S.; Vollinga, R. C.; Labarre, M.; Payza, K.; Terenius, L.; Luthman, K. Design, synthesis, and evaluation of Phe-Gly mimetics: Heterocyclic building blocks for pseudopeptides. J. Med. Chem. 1999, 42, 4331-4342.
29. The conformational analysis was performed in Macromodel (v. 5.5) using the AMBER force-field in vacuo. Conformations within a 3 kcal/mol range from the lowest conformation found were compared. See ref 28.
30. The semiempirical calculations were performed in the Spartan program (v. 5.1.3) using AM1 as approximate Hamiltonian. The atomic charges were calculated by electrostatic fitting of the single point energies of the minimized structures.
31. Saitton, S.; Kihlberg, J.; Luthman, K. A synthetic approach to 2,3,4-substituted pyridines useful as scaffolds for tripeptidomimetics. Tetrahedron 2004, 60, 6113-6120.
32. Rocca, P.; Marsais, F.; Godard, A.; Queguiner, G. Connection between metalation and cross-coupling strategies. A new convergent route to azacarbazoles. Tetrahedron 1993, 49, 49-64.
33. Rocca, P.; Cochennec, C.; Marsais, F.; Thomas-dit-Dumont, L.; Mallet, M.; Godard, A.; Queguiner, G. 1st Metalation of Aryl Iodides - Directed Ortho-Lithiation of Iodopyridines, Halogen-Dance, and Application to Synthesis. J. Org. Chem. 1993, 58, 7832-7838.
34. Trecourt, F.; Breton, G.; Bonnet, V.; Mongin, F.; Marsais, F.; Queguiner, G. Pyridylmagnesium chlorides from bromo and dibromopyridines by bromine - magnesium exchange: A convenient access to functionalized pyridines. Tetrahedron Lett. 1999, 40, 4339-4342.
35. Depostition number CCDC 243122 at the Cambridge Crystallographic Data Centre; web site (http://www.ccdc.cam.ac.uk).
36. Cram, D. J.; Elhafez, F. A. A. Studies in stereochemistry. X. The rule of "Steric control of asymmetric induction" in the synthesis of acyclic systems. J. Am. Chem. Soc. 1952, 74, 5828-5835.
37. Silyl-protecting groups used were TES (triethylsilyl), TBDMS (tertbutyldimethylsilyl), and TIPS (triisopropylsilyl).
38. Compare the ease of hydrolysis of the amide with the ease of forming the methyl ester in methanol. Presumably this is due to the intramolecular assistance of the pyridine nitrogen.
39. Weiner, D. M.; Burstein, E. S.; Nash, N.; Croston, G. E.; Currier, E. A.; Vanover, K. E.; Harvey, S. C.; Donohue, E.; Hansen, H. C.; Andersson, C. M.; Spalding, T. A.; Gibson, D. F. C.; Krebs-Thomson, K.; Powell, S. B.; Geyer, M. A.; Hacksell, U.; Brann, M. R. 5-hydroxytryptamine(2A) receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 2001, 299, 268-276.
40. Burstein, E. S.; BraunerOsborne, H.; Spalding, T. A.; Conklin, B. R.; Brann, M. R. Interactions of muscarinic receptors with the heterotrimeric G proteins G(q) and G(12): Transduction of proliferative signals. J. Neurochem. 1997, 68, 525-533.
41. Mishra, R. K; Marcotte, E. R.; Chugh, A.; Barlas, C.; Whan, D.; Johnson, R. L. Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG). Peptides 1997, 18, 1209-1215.
42. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3-25.
43. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
44. Palm, K.; Stenberg, P.; Luthman, K.; Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 1997, 14, 568-571.
45. Baures, P. W.; Ojala, W. H.; Gleason, W. B.; Mishra, R. K.; Johnson, R. L. Design, Synthesis, X.-Ray-Analysis, and Dopamine Receptor-Modulating Activity of Mimics of the C5 Hydrogen-Bonded Conformation in the Peptidomimetic 2-Oxo-3(R)-(2(S)-pyrrolidinylcarbonyl)amino-1-pyrrolidineacetamide. J. Med. Chem. 1994, 37, 3677-3683.
46. Otwinowski, Z.; Minor, W. Methods in Enzymology. In Macromolecular Crystallography; Carter, C. W., Jr., Sweet, R. M., Eds.; Academic Press: New York, 1997; Part A, pp 307-326.
47. Nonius B. V., "Collect" data collection software, 1999.
48. Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G. L.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A. G. G.; Polidori, G.; Spagna, R. SIR97: A new tool for crystal structure determination and refinement. J. Appl. Crystallogr. 1999, 32, 115-119.
49. Sheldrick, G. M. 1997. SHELXL-97. Program for the Refinement of Crystal Structures. University of Göttingen, Germany.
50. The program MAREA is available from J. Gråsjö, Department of Pharmaceutics, Uppsala University, Uppsala, Sweden (e-mail: johan. grasjo@farmaci.uu.se).
51. Dowty, E. 2000. ATOMS for Windows and Macintosh. Version 5.1. Shape Software, 521 Hidden Valley Road, Kingsport, TN 37663.